What is the recommended dose of levocetirizine (antihistamine) syrup in mg per kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Levocetirizine Syrup Dosing in Children

For children aged 6 months to 5 years, levocetirizine should be dosed at 0.125 mg/kg twice daily (equivalent to 0.25 mg/kg/day total), which provides comparable drug exposure to the standard adult dose of 5 mg once daily. 1, 2, 3

Age-Specific Dosing Recommendations

Infants 6-11 Months

  • 1.25 mg once daily using oral liquid drops 4
  • This fixed dose was well-tolerated in clinical trials with safety profiles similar to placebo 4

Children 1-5 Years

  • 1.25 mg twice daily (2.5 mg total daily dose) 2, 4
  • Alternatively, weight-based dosing of 0.125 mg/kg twice daily can be used 1, 2, 3

Children 6 Years and Older

  • 5 mg once daily (standard adult dose) 5

Pharmacokinetic Rationale for Weight-Based Dosing

The weight-based approach is critical in young children because:

  • Oral clearance increases by 0.044 L/h/kg with increasing body weight, meaning lighter children clear the drug faster relative to their size 1, 3
  • Volume of distribution increases by 0.639 L/kg with weight, requiring proportional dose adjustments 1, 3
  • Children aged 12-48 months receiving 0.125 mg/kg twice daily achieve the same drug exposure (AUC) as adults taking 5 mg once daily 3
  • The elimination half-life in toddlers is approximately 4.1 hours, shorter than in adults, supporting twice-daily dosing 2

Clinical Efficacy and Safety

Demonstrated Effectiveness

  • In children aged 6-12 years with seasonal allergic rhinitis, levocetirizine 5 mg once daily reduced total symptom scores by 94.1% relative to placebo over 2 weeks 6
  • Nasal congestion improved by 77.5% relative to placebo, with maximum benefit at 0.31 points on a 0-3 scale 6
  • Quality of life scores improved more with levocetirizine (0.85) than placebo (0.51) at 2 weeks, with sustained benefit through 6 weeks 6

Safety Profile

  • Treatment-emergent adverse events occurred at similar rates to placebo (33.7% vs 30.7%) in children aged 1-5 years 4
  • No clinically significant changes in vital signs, ECG parameters (including QT interval), or laboratory values were observed 4
  • The drug was well-tolerated for up to 18 months of continuous use in children as young as 12 months 1, 3

Special Considerations

Renal Impairment

  • Dose reduction is necessary in moderate renal impairment (creatinine clearance 10-50 mL/min), as levocetirizine is predominantly renally excreted 7
  • Consider halving the dose in these patients 7

Administration Timing

  • Evening or bedtime dosing may minimize any sedative effects, though levocetirizine is less sedating than first-generation antihistamines 7
  • For twice-daily dosing in young children, maintain 12-hour intervals between doses 2

Common Pitfalls to Avoid

  • Do not use once-daily dosing in children under 6 years: The shorter half-life (4.1 hours) in toddlers necessitates twice-daily administration for sustained symptom control 2
  • Avoid fixed adult doses in young children: Weight-based dosing ensures appropriate drug exposure, as clearance varies significantly with body weight 1, 3
  • Do not assume compliance without verification: In one study, 12% of instances showed suspected noncompliance with significantly reduced bioavailability 3

References

Research

Population pharmacokinetics of levocetirizine in very young children: the pediatricians' perspective.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005

Research

Levocetirizine in 1-2 year old children: pharmacokinetic and pharmacodynamic profile.

International journal of clinical pharmacology and therapeutics, 2005

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial.

Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2005

Guideline

Dosis y Administración de Levocetirizina

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.